Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Ottawa

$25,000.00

Targeted proteomics and miRNomics to tackle biomarkers of infectious and neurodegenerative diseases and cancer

EF 2022-23

Résumé
Nowadays, research on molecular biomarkers is widely recognized as fundamental to improving the prevention, diagnosis, prognosis, monitoring and treatment of infectious and neurodegenerative diseases, and cancer. This project is focused on the development of innovative analytical methods for purification, preconcentration, separation, identification and characterization in biological fluids of proteins, glycoproteins and miRNA biomarkers, specifically related to COVID-19 (spike glycoprotein and nucleocapside protein), sepsis (procalcitonin protein), Parkinsons and Alzheimers diseases (alpha-synuclein protein and clusterin glycoprotein, respectively), chronic lymphocytic leukemia (miR21) and colorectal cancer (carcinoembryonic antigen glycoprotein, miR-421, miR130b-3p and miR27a-3p). Different strategies will be investigated, including the direct analysis of the biomarkers at the intact level or by bottom-up approaches, after their enzymatic digestion to obtain characteristic fragments (e.g. peptides, phosphopeptides, glycopeptides or glycans). Likewise, possible differences and alterations in the structure, composition or concentration of the potential biomarkers will be evaluated from a comparison of control and pathological samples. For these purposes, it will be primarily used high-resolution microscale separation techniques coupled to mass spectrometry (capillary liquid chromatography and capillary electrophoresis coupled to mass spectrometry, CapLC-MS and CE-MS) in full scan MS and tandem MS/MS modes, and online purification and preconcentration techniques, such as on-line solid-phase extraction capillary electrophoresis-mass spectrometry (on-line SPE-CE-MS). Finally, the application of advanced data analysis tools will provide a more systematic and comprehensive interpretation of the enormous amount of complex multidimensional data generated in the different comparative MS-based studies.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
578469-2022
Name nom
Berezovski, Maxim MV
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
25000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Installment
inst:1
Partie
1
Nb partie
1
Application title
Targeted proteomics and miRNomics to tackle biomarkers of infectious and neurodegenerative diseases and cancer
Application summary
Nowadays, research on molecular biomarkers is widely recognized as fundamental to improving the prevention, diagnosis, prognosis, monitoring and treatment of infectious and neurodegenerative diseases, and cancer. This project is focused on the development of innovative analytical methods for purification, preconcentration, separation, identification and characterization in biological fluids of proteins, glycoproteins and miRNA biomarkers, specifically related to COVID-19 (spike glycoprotein and nucleocapside protein), sepsis (procalcitonin protein), Parkinsons and Alzheimers diseases (alpha-synuclein protein and clusterin glycoprotein, respectively), chronic lymphocytic leukemia (miR21) and colorectal cancer (carcinoembryonic antigen glycoprotein, miR-421, miR130b-3p and miR27a-3p). Different strategies will be investigated, including the direct analysis of the biomarkers at the intact level or by bottom-up approaches, after their enzymatic digestion to obtain characteristic fragments (e.g. peptides, phosphopeptides, glycopeptides or glycans). Likewise, possible differences and alterations in the structure, composition or concentration of the potential biomarkers will be evaluated from a comparison of control and pathological samples. For these purposes, it will be primarily used high-resolution microscale separation techniques coupled to mass spectrometry (capillary liquid chromatography and capillary electrophoresis coupled to mass spectrometry, CapLC-MS and CE-MS) in full scan MS and tandem MS/MS modes, and online purification and preconcentration techniques, such as on-line solid-phase extraction capillary electrophoresis-mass spectrometry (on-line SPE-CE-MS). Finally, the application of advanced data analysis tools will provide a more systematic and comprehensive interpretation of the enormous amount of complex multidimensional data generated in the different comparative MS-based studies.